Julie Chas<sup>1</sup>, Gilles Peytavin<sup>2</sup>, Diane Carette<sup>3</sup>, Nicolas Fabresse<sup>4</sup>, Isabelle Charreau<sup>3</sup>, Catherine Capitant<sup>3</sup>, Perrine Roux<sup>5</sup>, Eric Cua<sup>6</sup>, Laurent Cotte<sup>7</sup>, Armelle Pasquet<sup>8</sup>, François Raffi<sup>9</sup>, Laurence Meyer<sup>3</sup>, Gilles Pialoux<sup>1</sup>, Jean-Michel Molina<sup>10</sup>, Jean-Claude Alvarez<sup>4</sup>.





<sup>1</sup>Hôpital Tenon, Paris, France; <sup>2</sup> Hôpital Bichat–Claude Bernard, Paris, France; <sup>3</sup> Inserm SC10, Villejuif, France; <sup>4</sup>Hôpital de Garches, Paris, France; <sup>5</sup>INSERM, Marseille, France; <sup>6</sup>Hôpital de l'Archet, Nice, France; <sup>7</sup>Hôpital de la Croix Rousse, Lyon, France; <sup>8</sup>Hôpital Dron, Tourcoing, France; <sup>9</sup>Hôpital Hôtel Dieu, Nantes, France; <sup>10</sup>Hôpital Saint-Louis, Paris, France.

Introduction

- In the ANRS IPERGAY trial conducted among high risk MSM : 86% relative reduction of HIV-incidence was reported with on demand PrEP use with TDF/FTC.
- Use of Chemsex drugs is increasingly reported among MSM and is associated with higher risk behavior and lower use of condom.
- All previous studies are based on self-reported consumption data with auto-questionnaires. None of them evaluates qualitatively and quantitatively the prevalence of conventional drugs and new psychoactive substances (NPS) in MSM.

Methods

- During the ANRS IPERGAY trial, volunteers for substudy were asked every four month to provide hair samples to detect drugs (except the GHB/GBL, poppers and THC for technical reasons).
- When possible (hair length  $\geq$  3cm and weight  $\geq$  20mg) a segmental analysis was carried out, 1 cm corresponding to 1 month of drug use.
- After sample pretreatment (external decontamination, lavage and liquid-liquid extraction), a total of 86 molecules including conventional substances (cocaine, amphetamines, opiates), 31 New Psychoactive Substances (NPS) and therapeutics substances were screened by High Resolution mass spectrometry (Q-Exactive®) and quantified using Triple Quadripole TSQ Vantage<sup>®</sup> (ThermoFisher<sup>®</sup>) in MRM mode. The method was validated according to European Medicines Agency's guidelines.
- Only patients with NPS and/or conventional drugs detected in hair samples were considered as consumers (excluding therapeutics drugs).



- 69 volunteers were enrolled, among the 429 pts of the Ipergay study population.
- Baseline characteristics of the study participants are similar to the overall lpergay population (Table 1).

## Table 1. Baseline characteristics of the study participants. Median (IQR) or n (%).

		Drug Sub-study population (N=69)	Ipergay Not in drug substudy population (N=360)
Age (years), median, IQR		34.7 [28,0- 40,9]	35,2 [29,3- 42,8]
Sexual orientation	Homosexual	67 (97%)	347 (96%)
	Bisexual	2 (3%)	13 (4%)
Education level – no. (%), Postsecondary		45 (65%)	261 (74%)
Unemployed – no. (%),		15 (22%)	44 (12%)

- A total of 219 hair segments were analyzed.
- 32 molecules were detected : 15 NPS, 9 Therapeutics drugs and 8 Conventional drugs (Table 2).
- NPS and conventional drugs were detected in 77% (53/69) participants.
- NPS (especially cathinones) were detected in 39% (27/69) participants .

**P-**

value

0,21

1

0,28

0,06

Table	2.	Molecules	detected.
		molecules	acteuteut

DRUGS	N Pts	%	DRUGS	N Pts	%
COCAINE	47	68,1	METHOXETAMINE	4	5,8
MDMA	31	44,9	PHOLCODINE	4	5,8
KETAMINE	26	37,7	METHIOPROPAMINE	3	4,3
SILDENAFIL	23	33,3	ΡΜΜΑ	3	4,3
EPHEDRINE	18	26,1	MDPV*	3	4,3
TRAMADOL	15	21,7	METAMFEPRAMONE*	2	2,9
MEPHEDRONE*	14	20,3	VARDENAFIL	1	1,4
4 MEC*	12	17,4	5F-PB22	1	1,4
CODEINE	9	13,0	METHYLPHENIDATE	1	1,4
NEFOPAM	7	10,1	NALMEFENE	1	1,4
TADALAFIL	7	10,1	DIPHENIDINE	1	1,4
METHAMPHETAMINE	6	8,7	PHENDIMETRAZINE	1	1,4
ETHYLPHENIDATE	5	7,2	PHENTERMINE	1	1,4
AMPHETAMINE	4	5,8	n-METHYL-2AI	1	1,4
METHYLONE*	4	5,8	DIMETHYLONE*	1	1,4
DEXTROMETORPHANE	4	5,8	BUTORPHANOL	1	1,4
NPS (*c	athinones)	Therape	utics drugs	Conventional	drugs

- NPS intake was never isolate but associated to cocaine, MDMA or ketamine in 25/27 (93%), 20/27 • (74%), and 19/27 (70%) of cases respectively, showing poly-consumptions.
- Segmental hair analysis performed showed wide range exposures, ranging from unique intake • (concentration range 5-20 pg/mg) to chronic abuse (>90 ng/mg for amphetamines) but no increase of the quantity of drugs consumed per person in the time, except rare cases.
- No increase of the number of consumers in the time. •
- Drugs detection in our study is more important than the self-reported consumption of recreational drugs by questionnaire : 21/53 (39,6%) participants having drugs detected in hair samples didn't declare consumption in questionnaires. (Table 3).

### Table 3. Correlation between hair samples and self-reported questionnaires.

	Hair samples	Hair sample
	with drugs detected	without drugs detect
	N = 53	N = 16
Questionnaires with drugs consumption self-reported	32/69 (46%)	2/69 (4%)
Questionnaires without drugs consumption self-reported	21/69 (30%)	14/69 (20%

MSM pts consuming drugs have more differents partners in past 2 months (p<0,0001) (Table 4)

#### Table 4. Associations between drugs consumption and other sexual behaviours.

	Hair samples with drugs detected N = 53	Hair samples without drugs detected N = 16
No. of partners in past 2 months, median, IQR	7 [4-15]	5 [2-10]
No. of sexual acts in past 4 weeks, median, IQR	10 [5-15]	9 [4-15]
High-risk HIV exposure (only receptive anal sex) : Condomless receptive anal sex :	N =48/53	N = 16/16
Yes	33	9
No	15	7
Hardcore sexual practices Yes No	21 32	4 12
Fist sexual practices		
Yes	25	4
Νο	28	12

## Conclusion

- Prevalence of NPS and especially synthetic cathinones use in the MSM PreP population is high but lower than conventional drugs like cocaine and amphetamine, especially MDMA.
- Hair analysis reflects objectively drugs consumption more higher than the self-reported consumption, under-reporting connected with desirability bias, memory or knowledge of actuals products consumed. Observed consumptions suggest to review risk reduction strategy against drug consumption.

# Acknowledgments

 This work was supported by ANRS and by a Acknowledgements to The Participants, The Study Staff and Peer-Counselors, The Trial Scientific Committee, The DSMB, The Community Advisory Board, The ANRS Staff and INSERM SC10-US19.













